Opinion|Videos|August 28, 2024
Overview of CAR T-cell Therapy Options in R/R MM
The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.
Advertisement
Video content above is prompted by the following:
- What current CAR T- cell therapy options are there for r/r MM? [EX1]
- Resource Link:
CARVYKTI (cilta-cel) HCP website - Reource Link:
ABECMA (ide-cel) HCP website
- Resource Link:
- What are some challenges with CAR T-cell therapy in r/r MM that you’ve experienced in your clinical practice? What are some potential resources and/or strategies to help support logistical challenges or early referral?
- What is the role of bridging therapy prior to CAR T-cell therapy?
- How do you define “bridging therapy”?
- What is the potential role of Selinexor as bridging therapy, and how have you incoporated it in your practice?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
3
Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC
4
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
5